They are developing a mammalian synthetic biology platform––from cells to software––to enable biotechnologies with outsized impact, with an initial focus on gene therapies, cell therapies, and protein therapeutics. During his PhD in the Voigt Lab at MIT, he created foundational design tools in synthetic biology that laid the basis for Asimov.
